Forgot Password?
Return to Course Listing

CME: Updates in the management of polyneuropathy of hereditary transthyretin amyloidosis (ATTR): Treating the condition head-on

ACCREDITATION EXPIRED: January 14, 2025

Activity Description / Statement of Need:

In this online, self-learning activity:

Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. Transthyretin (TTR) is a protein present in human serum whose role is to transport thyroxine and retinol-binding proteins, and it is vital for behavior, cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations. The hereditary form of ATTR (ATTRv) is passed to offspring through autosomal dominant inheritance and may present as late as mid-adulthood, but its symptoms usually start between the ages of 2 and 10 years. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.

Target Audience:

The following HCPs: neurologists and hematologists; physician assistants, nurse practitioners, nurses, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.


Commercial Support Disclosure: This program is supported by an educational grant from Ionis.

This activity is free of charge.


Release Date: January 14, 2023 -- Expiration Date: January 14, 2025

Faculty: Chafic Karam, MD

Agenda

Introduction, disclosures

Introduction content: Cursory refresher and review of ATTRv & ATTRv-PN

  • Epidemiology of ATTRv
  • Pathophysiology
  • Recognition of ATTRv and ATTRv-PN: symptomology and diagnosis
  • Progression of the condition

Treatment in patients with ATTRv-PN

  • Changes in approach to ATTR & ATTRv-PN in recent years
  • Present and emerging pharmacotherapy and research findings: antisense oligonucleotides, RNA interference, TTR stabilizers, gene therapy
  • Best practice: putting it all together
  • Patient cases

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall challenges and barriers to care associated with the identification and management of ATTRv-PN.
  • Recall present treatment options for ATTRv-PN.
  • Formulate a treatment plan for a patient with ATTRv-PN.

Accreditation

ACCME Activity #202377680

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Chafic Karam, MD, Associate Professor of Clinical Neurology, University of Pennsylvania Perelman School of Medicine, has received financial compensation for research and/or consulting work from Alnylam, Ionis, Argenx, and Genzyme.

 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Ionis.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Transthyretin amyloidosis (ATTR): Prompt diagnosis, contemporary management strategies, and their impact on patient outcomes

Contemporary challenges and updates and in the diagnosis and management of Alzheimer’s disease – from early disease onward

Sickle cell disease (SCD): A focus on updates in therapy

Myeloma bone disease: Monitoring and management